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1. INTRODUCTION {#gcc22668-sec-0001}
===============

Ovarian sarcomas are rare mesenchymal tumors, and various histological types---such as carcinosarcoma,[1](#gcc22668-bib-0001){ref-type="ref"} leiomyosarcoma,[2](#gcc22668-bib-0002){ref-type="ref"} rhabdomyosarcoma,[3](#gcc22668-bib-0003){ref-type="ref"}, [4](#gcc22668-bib-0004){ref-type="ref"} endometrial stromal sarcoma[5](#gcc22668-bib-0005){ref-type="ref"} and fibrosarcoma[6](#gcc22668-bib-0006){ref-type="ref"}---are pathologically defined. Small round cell sarcoma is a heterogeneous group of tumors arising from various sites, and the prognosis of this disease is poor.[7](#gcc22668-bib-0007){ref-type="ref"}, [8](#gcc22668-bib-0008){ref-type="ref"} Fusion genes resulting from chromosomal rearrangements have been considered as a significant oncogenic factor in many mesenchymal malignancies,[9](#gcc22668-bib-0009){ref-type="ref"} and tumor‐specific fusion genes contribute to the classification of small round cell sarcomas into several histologic subtypes,[8](#gcc22668-bib-0008){ref-type="ref"} that is, *EWSR1*--*FLI1* fusion in Ewing sarcoma[10](#gcc22668-bib-0010){ref-type="ref"} and *PAX3/8* fusions in alveolar rhabdomyosarcoma.[11](#gcc22668-bib-0011){ref-type="ref"}

Recent advances in sequencing technology have enabled the comprehensive detection of fusion genes in the cancer genome and transcriptome. We have used RNA sequencing data to identify numerous fusion genes in various types of tumors[12](#gcc22668-bib-0012){ref-type="ref"}, [13](#gcc22668-bib-0013){ref-type="ref"}, [14](#gcc22668-bib-0014){ref-type="ref"} and developed the fusion gene data portal.

Herein, we report the molecular characteristics of an ovarian undifferentiated small round cell sarcoma based on genomic and transcriptomic analyses.

2. MATERIALS AND METHODS {#gcc22668-sec-0002}
========================

2.1. Case presentation {#gcc22668-sec-0003}
----------------------

We describe a case of 34‐year‐old woman who did not have a significant past medical history or family history. She visited a gynecologist for cancer screening with no symptom. The Pap test was negative, but transvaginal ultrasound examination revealed a large pelvic mass in the pouch of Douglas with ascites. Moreover, transabdominal ultrasound examination also revealed a large mass in the abdominal cavity. Her serum CA125 level was elevated (969 U/mL). MR and CT imaging detected an 8‐cm‐sized tumor that was suspected to be derived from the right ovary in the right‐side pelvic cavity, a 6‐cm‐sized tumor in the lower abdominal cavity, diffuse peritoneal thickening, and ascites. On the other hand, no obvious abnormal findings were noted in the uterus, the left adnexa, and soft tissue (Figure [1](#gcc22668-fig-0001){ref-type="fig"}A). She was suspected to have cancer of unknown primary origin and was referred to our hospital for further examinations and treatment of this tumor. To confirm a pathological diagnosis, she underwent an exploratory laparotomy. Operative findings revealed \~2350 mL of bloody ascites in the peritoneal cavity, and the ascites cytology was positive for malignant cells. An 8 cm right ovarian solid tumor adhered to the small intestine at multiple sites. Omental cake and diffuse peritoneal dissemination were also observed but their sizes were significantly smaller than the size of the right ovarian solid tumor. A normal‐sized uterus and left adnexa strongly adhered to the right ovarian tumor. We performed partial resection of the right ovarian tumor and biopsy of omental cakes (Figure [1](#gcc22668-fig-0001){ref-type="fig"}B). Pathological findings demonstrated that tumor tissue consisted of small round cells with abundant eosinophilic cytoplasm and spindle cells, and the cell‐to‐cell junction was unclear in this tumor (Figure [2](#gcc22668-fig-0002){ref-type="fig"}A). Immunohistochemistry analysis revealed that tumor cells were positive for vimentin, weakly positive for CD99, and negative for pan‐keratin (AE1/AE3), CD10, desmin, MyoD1, myogenin, and SMA (Figure [2](#gcc22668-fig-0002){ref-type="fig"}B and Supporting Information, Figure [1](#gcc22668-supitem-0001){ref-type="supplementary-material"}). Finally, the patient was diagnosed with a stage IIIC ovarian undifferentiated small round cell sarcoma. After the surgery, she was treated with combination chemotherapy, including Ifosfamide and Epirubicin. After 6 courses of the chemotherapy, the tumor size increased, and massive ascites was observed. She did not desire additional therapies. Finally, she died 9 months after the surgery.

![MR imaging and surgical findings. A, T2‐weighted sagittal and axial MRIs are presented. An 8 cm tumor was detected in the right‐side pelvic cavity (yellow arrowhead) and a 6 cm tumor was detected in the lower abdominal cavity (yellow allow). Diffuse peritoneal thickening and ascites were also detected (red arrow). No obvious abnormal findings were noted in the uterus (U) and the left adnexa (L). B, An 8 cm right ovarian solid tumor adhered to small intestine (yellow arrowhead) and Omental cake (yellow arrow) \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-557-g001){#gcc22668-fig-0001}

![Histological and immunohistochemical findings. A, Representative images of H&E staining. Tumor consisted of small round cells with abundant eosinophilic cytoplasm or spindle cells. Cell‐to‐cell junctions were unclear. (100× and 400× magnification; scale bar, 100 μm). B, Immunohistochemical analysis revealed positive staining for vimentin and negative staining for cytokeratin AE1/AE3 (400× magnification; scale bar, 100 μm) \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-557-g002){#gcc22668-fig-0002}

2.2. Clinical samples {#gcc22668-sec-0004}
---------------------

The institutional review board approved this study (No. 682 and 837 in Niigata University and No. 29‐16 in National Institute of Genetics). The patient provided written informed consent for the collection of samples and subsequent analysis. Frozen tumor and matched normal blood samples were obtained at the Niigata University Medical and Dental Hospital.

2.3. Whole‐exome sequencing and analysis {#gcc22668-sec-0005}
----------------------------------------

Two hundred nanograms of DNA from a patient with ovarian sarcoma and her normal blood sample were used for preparing sequencing libraries using the SureSelect XT Reagent Kit (Agilent Technologies, Santa Clara, CA). Target‐gene enrichment was conducted with SureSelect Human All Exon V5 + lncRNA Kit (Agilent Technologies). The libraries were sequenced with the 2 × 100 bp paired‐end module on the Illumina HiSeq 2500 platform (Illumina).

The Illumina adapter and low‐quality sequences were trimmed using Trimmomatic.[15](#gcc22668-bib-0015){ref-type="ref"} The paired‐end reads were aligned to the human reference genome (hg19) using Burrows‐Wheeler Aligner (BWA).[16](#gcc22668-bib-0016){ref-type="ref"} The aligned reads were processed for removal of PCR duplicates using Picard tools (<http://broadinstitute.github.io/picard>). Local realignments and base‐quality recalibrations were conducted using Genome Analysis Toolkit (GATK).[17](#gcc22668-bib-0017){ref-type="ref"}, [18](#gcc22668-bib-0018){ref-type="ref"} Somatic single‐nucleotide variants (SNVs) and short insertions and deletions (indels) were called using Strelka.[19](#gcc22668-bib-0019){ref-type="ref"} Functional annotation of the identified somatic variants was implemented by ANNOVAR.[20](#gcc22668-bib-0020){ref-type="ref"}

2.4. Detection of putative somatic copy number alterations {#gcc22668-sec-0006}
----------------------------------------------------------

We performed copy number analyses using whole‐exome sequencing data with Control‐FREEC.[21](#gcc22668-bib-0021){ref-type="ref"}, [22](#gcc22668-bib-0022){ref-type="ref"} The aligned read data from the ovarian sarcoma sample and the matched normal blood sample were used. The sites of the germline variants identified in the matched normal sample were examined for beta allele frequency (BAF) profiles. A threshold of ≥6 copies for gene amplification was used.[23](#gcc22668-bib-0023){ref-type="ref"} Cancer‐associated genes that were annotated in OncoKB[24](#gcc22668-bib-0024){ref-type="ref"} were focused in this study.

2.5. RNA sequencing {#gcc22668-sec-0007}
-------------------

Total RNA was extracted from frozen a sample using TRIzol (Invitrogen, Carlsbad, CA). The quantity and quality of the extracted RNA were evaluated using the RNA 6000 Nano Assay Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA integrity value of our sample was 9.8. One microgram of extracted total RNA was used for library preparation, which was conducted using the TruSeq Stranded mRNA Library Prep Kit (Illumina, San Diego, CA) according to the manufacturer\'s protocol. The modal size of the library was \~300 bp. The adapter‐ligated cDNA was amplified with 12 cycles of PCR. The samples were sequenced on the Illumina HiSeq 2500 platform with the 2 × 100 bp paired‐end read module.

We applied the Pipeline for RNA sequencing Data Analysis (PRADA)[25](#gcc22668-bib-0025){ref-type="ref"} to data from the above RNA sequencing experiments and obtained a list of fusion transcripts and gene expression data for each sample.

2.6. Reverse transcriptase polymerase chain reaction (RT‐PCR) and Sanger sequencing {#gcc22668-sec-0008}
-----------------------------------------------------------------------------------

RT‐PCR and Sanger sequencing were performed as previously reported.[13](#gcc22668-bib-0013){ref-type="ref"}, [14](#gcc22668-bib-0014){ref-type="ref"} In brief, total RNA (1 μg) was reverse‐transcribed into cDNA (corresponding to 10 ng of total RNA) using Prime Script II Reverse Transcriptase (Takara Bio, Shiga, Japan). cDNA was subjected to PCR amplification using KAPA Taq DNA polymerase (KAPA Biosystems, Woburn, MA). The reactions were performed in a thermal cycler under the following conditions: 40 cycles at 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute with a final extension at 72°C for 1 minute. PCR products were extracted and purified using NucleoSpin Gel and PCR Clean‐up (Takara Bio) and sequenced on an ABI 3130xl DNA Sequencer (Applied Biosystems, Foster City, CA) using a BigDye Terminator kit (Applied Biosystems). The PCR primers used in this study are presented in Supporting Information, Table [1](#gcc22668-supitem-0004){ref-type="supplementary-material"}.

2.7. Quantitative real‐time RT‐PCR {#gcc22668-sec-0009}
----------------------------------

Quantitative real‐time RT‐PCR was performed using the Thermal Cycler Dice Real‐Time System III (Takara Bio). cDNA (corresponding to 10 ng of total RNA) was subjected to real‐time PCR analysis with SYBR Premix Ex Taq II (Takara Bio). The relative quantification method was used to measure the amounts of the respective genes normalized to *ACTB.* The primers used in this study are presented in Supporting Information, Table [1](#gcc22668-supitem-0004){ref-type="supplementary-material"}.

![Identification of the *MXD4‐NUTM1* fusion gene. A, Identification of the *MXD4--NUTM1* fusion transcripts through RT‐PCR and Sanger sequencing. An electropherogram demonstrated the junction point of two genes. B, The schematics of *MXD4--NUTM1* fusion transcript. The bHLH domain in *MXD4* and pro‐rich domain in *NUTM1* were retained in the *MXD4--NUTM1* fusion transcript. C, Relative *NUTM1* mRNA expression in the undifferentiated ovarian small round cell sarcoma reported in this study compared with epithelial ovarian cancers. Ovarian sarcoma denotes the present case. HGS and CCC denote high‐grade serous carcinoma and clear cell carcinoma, respectively. D, Immunohistochemical staining revealed high expression of NUTM1 with speckled nuclear pattern in the ovarian undifferentiated small round cell sarcoma reported in this study (400× magnification; scale bar, 100 μm) \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-557-g003){#gcc22668-fig-0003}

2.8. Immunohistochemical staining {#gcc22668-sec-0010}
---------------------------------

Histological specimens were reviewed by a gynecologic pathologist (TM). In addition, immunohistochemical staining for the NUTM1 protein was performed as previously reported.[14](#gcc22668-bib-0014){ref-type="ref"}, [26](#gcc22668-bib-0026){ref-type="ref"} Briefly, after deparaffinization, antigen retrieval was performed with Target Retrieval Solution (10 mM citrate buffer, pH 6.0; Dako) in a microwave for 30 minutes at 96°C. Subsequently, the sections were incubated overnight with primary antibody (C52B1, Cell signaling technology; dilution ratio 1:50) at 4°C. Then, biotinylated anti‐mouse secondary antibodies (Vector Laboratories, Burlingame, CA) were added followed by incubation with ABC reagent (Dako) and 3,3′‐diaminobenzidine (Sigma, St. Louis, MO). Slides were counterstained with hematoxylin. When most of cells were stained, the sample was considered positive. Otherwise, the result was considered negative.

2.9. Western blotting {#gcc22668-sec-0011}
---------------------

Western blotting experiments for NUTM1 (C52B1, Cell signaling technology; dilution ratio 1:1000) and anti‐glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) antibody, clone 6C5 (MAB374, Merck Millipore Headquarters; dilution ratio 1:1000) were performed as previously reported.[13](#gcc22668-bib-0013){ref-type="ref"}, [14](#gcc22668-bib-0014){ref-type="ref"}, [26](#gcc22668-bib-0026){ref-type="ref"} Tissues were lysed in RIPA buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 1% Nonidet P‐40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate \[SDS\], and 1 mM EDTA) supplemented with protease inhibitors (Roche). The lysates were separated by SDS--polyacrylamide gel electrophoresis on 5%‐20% gradient gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). Blots were then incubated with either anti‐mouse or anti‐rabbit horseradish peroxidase‐conjugated secondary antibodies (NA931 and NA934, GE Healthcare; dilution ratio 1:10 000), and visualized by chemiluminescence. Images have been cropped for presentation, and full‐size images are presented in Supporting Information, Figure [3](#gcc22668-supitem-0003){ref-type="supplementary-material"}.

3. RESULTS {#gcc22668-sec-0012}
==========

We performed whole exome sequencing of tumor and matched normal blood samples. We identified 8 nonsynonymous somatic mutations, and mutations were either missense or nonsense changes (Table [1](#gcc22668-tbl-0001){ref-type="table"}). A stopgain mutation in *PRUNE2* (also known as *BMCC1*) that had an important role in regulating differentiation, survival, and aggressiveness of the tumor cells[27](#gcc22668-bib-0027){ref-type="ref"} was detected. In addition, genome‐wide copy number analysis revealed that several cancer‐associated genes such as *ARID1B*, *LATS1*, *PRDM1*, *CDKN2A*, and *CDKN2B* were harbored heterozygous deletions (Supporting Information, Table [2](#gcc22668-supitem-0005){ref-type="supplementary-material"}). However, neither high‐level amplification genes (≥6 copies) nor homozygous deletion genes were detected.

###### 

A list of 8 nonsynonymous mutations identified by whole exome sequencing

  Gene         Chr     Pos         Effect                     Function in uniprot                                                          Turnor_alt_freq   Accession number
  ------------ ------- ----------- -------------------------- ---------------------------------------------------------------------------- ----------------- ------------------
  *COL9A1*     chr6    70935689    exon31: c.C1798T:p.R600C   Structural component of hyaline cartilage and vitreous of the eye            0.42              NM_078485
  *PRUNE2*     chr9    7932190     exon8:c.G5400A:p.W1800X    Regulating differentiation, survival and aggressiveness of the tumor cells   0.38              NM_001308048
  *C3orf56*    chr3    126915725   exon2:c.G197A:p.G66E       NA                                                                           0.23              NM_001007534
  *AGPAT5*     chr8    6588234     exon3:c.G292T:p.D98Y       Converts lysophosphatidic acid (LPA) into phosphatidic acid                  0.21              NM_018361
  *ARHGEF17*   chr11   73073554    exon14:c.G4771A:p.A1591T   Acts as guanine nucleotide exchange factor (GEF) for RhoA GTPases            0.21              NM_014786
  *TBC1D10B*   chr16   30380744    Exon1: c.C761T:p.P254L     Acts as GTPase‐activating protein for RAB3A, RAB22A, RAB27A, and RAB35       0.17              NM_015527
  *PER3*       chr1    7890053     Exon19:c.G3046A:p.A1016T   Component of the circadian clock, internal time‐keeping system               0.04              NM_001289862
  *PER3*       chr1    7890026     Exon19:c.A3019G:p.K1007E   Component of the circadian clock, internal time‐keeping system               0.04              NM_001289862

Next, we performed RNA sequencing of the tumor sample and identified two high‐confidence in‐frame fusion transcripts using the PRADA[25](#gcc22668-bib-0025){ref-type="ref"} (Table [2](#gcc22668-tbl-0002){ref-type="table"}). Using RT‐PCR and Sanger sequencing (Figure [2](#gcc22668-fig-0002){ref-type="fig"}A and Supporting Information, Figure [2](#gcc22668-supitem-0002){ref-type="supplementary-material"}), we validated two in‐frame fusion transcripts: *MXD4--NUTM1* (exon5--exon2) and *ARL6--POT1* (exon2--exon8). Given that the *NUTM1* rearrangement was considered as an oncogenic driver event and an attractive therapeutic target in "NUT midline carcinoma (NMC),"[28](#gcc22668-bib-0028){ref-type="ref"}, [29](#gcc22668-bib-0029){ref-type="ref"} we focused on the *MXD4--NUTM1* fusion transcript to perform subsequent analyses. The transcript allele fraction (TAF) score[13](#gcc22668-bib-0013){ref-type="ref"} for the *NUTM1* was 0.57, suggesting that both *MXD4--NUTM1* and wild‐type *NUTM1* were expressed in this tumor (Table [1](#gcc22668-tbl-0001){ref-type="table"}). Next, we compared *NUTM1* mRNA expression between this tumor and 10 epithelial ovarian cancer samples using quantitative real‐time PCR. We used the primers targeting common sequences of both *MXD4--NUTM1* fusion and wild‐type *NUTM1. NUTM1* mRNA expression levels in ovarian undifferentiated small round cell sarcoma were considerably increased compared with epithelial ovarian cancer samples (Figure [2](#gcc22668-fig-0002){ref-type="fig"}C). Moreover, immunohistochemistry analysis and Western blotting revealed high NUTM1 protein expression in this tumor (Figure [2](#gcc22668-fig-0002){ref-type="fig"}D and Supporting Information, Figure [3](#gcc22668-supitem-0003){ref-type="supplementary-material"}).

###### 

A list of 3 novel fusion transcripts identified by RNA sequencing

  5′ gene   3′ gene      Locus 5′ gene   Locus 3′ gene   Discordant read (n)   Junction spanning read (n)   maxTAF 5′ gene   maxTAF 3′ gene   Frame
  --------- ------------ --------------- --------------- --------------------- ---------------------------- ---------------- ---------------- ----------
  *MXD4*    *NUTM1*      4p16.3          15q.14          7                     22                           0.0594           0.5714           In‐frame
  *ARL6*    *POT1*       3q11.2          7q.31.33        5                     6                            0.25             0.13             In‐frame
  *POT1*    AC110491.1   7q.31.33        4p16.3          2                     8                            0.0278           0.0081           NA

4. DISCUSSION {#gcc22668-sec-0013}
=============

In this study, we clarified the molecular characteristics of an ovarian undifferentiated small round cell sarcoma using whole exome and RNA sequencing. Although we could not exclude the possibility of metastatic sarcoma in the right ovary completely, we diagnosed an ovarian sarcoma on the basis of clinicopathological findings. We identified a nonsense mutation in *PRUNE2* that was reported to be a potentially oncogenic[30](#gcc22668-bib-0030){ref-type="ref"} but not therapeutically targetable mutated genes at that time. No somatic mutation of cancer‐associated genes frequently mutated in epithelial ovarian cancer---such as *TP53,* [31](#gcc22668-bib-0031){ref-type="ref"} *KRAS,* [32](#gcc22668-bib-0032){ref-type="ref"} *PIK3CA*,[33](#gcc22668-bib-0033){ref-type="ref"} and *ARID1A* [34](#gcc22668-bib-0034){ref-type="ref"}---was detected.

On the other hand, we identified a novel *MXD4--NUTM1* fusion transcript. *NUTM1* (NUT midline carcinoma family member 1, also known as *C15orf55* or *NUT*), which maps to chromosome15q14, is typically expressed in a normal testis but not expressed in many other normal and malignant tissues.[35](#gcc22668-bib-0035){ref-type="ref"}, [36](#gcc22668-bib-0036){ref-type="ref"} *NUTM1* rearrangements causes "*NUT* midline carcinoma," which is an aggressive lethal malignancy that occurs in midline anatomical structures, especially the mediastinum, head, and neck.[37](#gcc22668-bib-0037){ref-type="ref"}, [38](#gcc22668-bib-0038){ref-type="ref"} Approximately two‐thirds of NMC cases harbor a *BRD4--NUTM1* fusion gene, which has been functionally validated as an oncogenic event.[39](#gcc22668-bib-0039){ref-type="ref"}, [40](#gcc22668-bib-0040){ref-type="ref"} In the other one‐third of cases, several fusion partners of *NUTM1* have been reported in the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (<http://cgap.nci.nih.gov/Chromosomes/Mitelman>) and recent papers, such as *ACIN1,* [41](#gcc22668-bib-0041){ref-type="ref"}, [42](#gcc22668-bib-0042){ref-type="ref"}, [43](#gcc22668-bib-0043){ref-type="ref"} *BCOR1,* [44](#gcc22668-bib-0044){ref-type="ref"} *BRD3,* [40](#gcc22668-bib-0040){ref-type="ref"} *BRD9,* [41](#gcc22668-bib-0041){ref-type="ref"} *BPTF,* [45](#gcc22668-bib-0045){ref-type="ref"} *CIC,* [46](#gcc22668-bib-0046){ref-type="ref"} *CUX1,* [42](#gcc22668-bib-0042){ref-type="ref"} *IKZF1,* [42](#gcc22668-bib-0042){ref-type="ref"}, [47](#gcc22668-bib-0047){ref-type="ref"} *MXD1,* [44](#gcc22668-bib-0044){ref-type="ref"} *NSD3,* [48](#gcc22668-bib-0048){ref-type="ref"} *SLC12A6,* [42](#gcc22668-bib-0042){ref-type="ref"} *ZNF532,* [49](#gcc22668-bib-0049){ref-type="ref"} and *ZNF618.* [42](#gcc22668-bib-0042){ref-type="ref"} Although *MXD1--NUTM1* fusion has been reported in gastric sarcoma, *MXD4* has not been previously reported as a fusion partner of *NUTM1.* Both *MXD1* and *MXD4* are members of the MAD gene family and regulate *MYC*, leading to cell growth in differentiating tissues.[50](#gcc22668-bib-0050){ref-type="ref"} Grayson et al. have identified that *MYC* is a key transcriptional target of *BRD4--NUTM1* fusion and that dysregulation of *MYC* by *BRD4--NUTM1* fusion has a central role in the pathogenesis of in *NUT* midline carcinoma.[51](#gcc22668-bib-0051){ref-type="ref"} Our data revealed an increase in both *NUTM1* mRNA and protein expression in tumor tissue. Further functional analysis focusing on *MYC* is needed to prove the significance of *NUTM1* fusions whose partners were the MAD gene family such as *MXD1* or *MXD4* in tumorigenesis, especially sarcomagenesis.

In general, NMC defined by the *NUTM1*‐fusion gene is histologically epithelial malignancy, especially squamous cell carcinoma that reacts with the antibodies to cytokeratin AE1/AE3 and p63 focally but not myogenin, SMA, chromogranin, synaptophysin, c‐kit, desmin, S‐100, and CD99.[28](#gcc22668-bib-0028){ref-type="ref"}, [52](#gcc22668-bib-0052){ref-type="ref"} Most recently, six cases of soft tissue and visceral neoplasms harboring *NUTM1* fusion genes have been reported. These tumors occurring outside the anatomic midline were diagnosed with undifferentiated tumors based on histological and immunohistochemical findings, and these tumors are suggested to be "*NUT*‐associated tumors."[44](#gcc22668-bib-0044){ref-type="ref"} Our case harboring the *NUTM1* fusion gene would also be classified as a "*NUT*‐associated tumor," and undifferentiated mesenchymal, neuroendocrine, and epithelial tumors should be reassessed by immunohistochemical and fusion gene analyses because "*NUT*‐associated tumors" may be underdiagnosed.[44](#gcc22668-bib-0044){ref-type="ref"}

We also identified an *ARL6--POT1* fusion transcript. *ARL6* (ADP‐ribosylation factor‐like protein 6),[53](#gcc22668-bib-0053){ref-type="ref"} which maps to chromosome 3q11, plays essential roles in modulating membrane trafficking and cytoskeletal function. *POT1* (protection of telomeres), which maps to chromosome 7q31, has an important role maintaining chromosome stability, and *POT1* mutations lead to tumorigenesis in various cancers.[54](#gcc22668-bib-0054){ref-type="ref"}, [55](#gcc22668-bib-0055){ref-type="ref"} Although each function of a fused gene may be important in tumorigenesis, we did not focus on the *ARL6--POT1* fusion in this study, given that no previous report suggesting oncogenic functions of *APL6* fusions or *POT1* fusions was available.

Comprehensive genome and transcriptome analysis of one case with ovarian undifferentiated small round cell sarcoma demonstrated unique molecular characteristics, such as a *PRUNE2* mutation or *MXD4--NUTM1* fusion. More extensive genomic and transcriptomic analyses for a large data set of ovarian undifferentiated small round cell sarcomas would lead to elucidation of the pathogenesis of this rare disease.
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